Meijer is working with Homeward, a technology-enabled rural health platform that helps residents who are facing significant health and economic disparities.
Bio-Thera is responsible for the development and manufacturing of the product, while Hikma is responsible for the commercialization in the United States.
The agreement includes proposed biosimilars to Ilaris (canakinumab), Kesimpta (ofatumumab) and an additional early-stage undisclosed biosimilar candidate.
The FDA is using Elsa to accelerate clinical protocol reviews, shorten the time needed for scientific evaluations and identify high-priority inspection targets.
